5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso
  • Mariangela Greco
    Affiliation not present
  • Marianna Criscuolo
    Affiliation not present
  • Luana Fianchi
    Affiliation not present
  • Livio Pagano
    Affiliation not present


Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but  there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.


CMML, 5-azacytidine

Full Text:

Submitted: 2014-06-12 16:04:39
Published: 2011-03-14 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185